香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 ProteLight Pharmaceuticals (Jiangsu) Co., Ltd. 普萊醫藥（江蘇）股份有限公司 （「本公司」） （於中華人民共和國境內註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的 要求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代 表 閣下知悉、接納並向本公司、本公司的獨家保薦人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據與香港公司註冊處處長註冊的 本公司招股章程作出投資決定；招股章程的文本將於發售期內向公眾人士提供。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據本文 件中的資料作出任何投資決定； ...

香港交易及結算所有限公司、香港聯合交易所有限公司與證券及期貨事務監察委員會對本公告的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 ProteLight Pharmaceuticals (Jiangsu) Co., Ltd. 普萊醫藥（江蘇）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 警告 本公告乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」） 的要求而刊發，僅用作向香港公眾人士提供資訊。 閣 下 覽 閱 本 公 告，即 表 示 閣 下 確 認、 接 納 及 同 意 普 萊 醫 藥（江 蘇）股 份 有 限 公 司 （「本公司」）、其獨家保薦人、保薦人兼整體協調人、整體協調人、顧問或包銷集團成員以下 各項： 在根據香港法例第32章《公司（清盤及雜項條文）條例》於香港公司註冊處處長登記本公司招股 章程前，概不會向香港公眾人士作出任何要約或邀請。倘於適時向香港公眾人士提出要約或 邀請，有意投資者務請僅依據於香港公司註冊處處長註冊的本公司招股章程作出投資決定， 招股章程 ...

阿通社2月9日消息，阿联酋国务部长兼药品管理局董事会主席赛义德·本·穆巴拉克·哈杰里在2026年 世界卫生博览会期间，正式启动阿联酋药品管理局重点项目"整体国家制造项目"。该项目旨在提升本国 药品和医疗产品制造能力，强化供应链安全与产业本地化。项目在统一框架下整合了监管、制造、质量 和监督体系，覆盖原料、生产、包装、储运全链条，并支持"一体化健康"理念。阿联酋药品管理局表 示，该举措将增强产业韧性，提升制药业国际竞争力，并巩固阿联酋作为区域先进制药制造中心的地 位。 （原标题：阿联酋启动"整体国家制造项目"推动制药业发展） ...

Core Viewpoint - The company reported a revenue decline of 16.12% in 2025, with a net profit loss of 55.84 million yuan, although it reduced its loss by 24.94% compared to the previous year [1] Financial Performance - In 2025, the company achieved a revenue of 433 million yuan, down from the previous year [1] - The net profit attributable to shareholders was -55.84 million yuan, indicating a reduction in losses compared to the previous year [1] - The company has experienced consecutive losses for four years, with net profits of -48.91 million yuan in 2022, -12.20 million yuan in 2023, -74.40 million yuan in 2024, and -55.84 million yuan in 2025 [2] Legal Issues - The former actual controller of the company was sentenced for damaging the company's interests, involving illegal financial activities that misappropriated company funds for personal use [3][4] - The court sentenced the former chairman to three years in prison and imposed a fine of 5 million yuan, while the former financial director received a sentence of one year and six months with a fine of 200,000 yuan [4] - The company received 62 million yuan in execution funds from the court as a result of the legal proceedings [5] Market Performance - As of the close on February 12, the company's stock price fell by 1.92%, trading at 9.18 yuan per share, with a total market capitalization of 1.138 billion yuan [6]

Company Developments - Bayer's new oral anticoagulant Asundexian has completed Phase 3 clinical trials and is expected to receive FDA approval by the end of 2026, viewed as a key product with blockbuster potential [2] - The company plans to achieve five significant milestones in the first half of 2026, focusing on expanding indications for existing products and releasing new data to strengthen its position in innovative drug development [2] Strategic Initiatives - Bayer's Dynamic Shared Responsibility (DSO) operational model, initiated in 2023, aims to save €2 billion annually starting in 2026 through organizational streamlining and improved decision-making efficiency [3] - The company will continue to focus on four strategic areas: innovation, addressing litigation issues in the U.S., improving cash flow, and enhancing profitability in its crop science business, with the pharmaceutical sector (especially in oncology, cardiovascular, neuroscience, and rare diseases) seen as a core growth engine [3] Company Status - Bayer has divested non-core assets, such as the global business of the antibiotic moxifloxacin, to concentrate resources on its more promising innovative drug pipeline [4] Future Outlook - Bayer's core products, rivaroxaban (Xarelto) and aflibercept (Eylea), will continue to face sales pressure from generic competition in 2026, although the company anticipates that this pressure will gradually ease after 2026 [5] - Ongoing litigation related to glyphosate from the acquisition of Monsanto remains a significant uncertainty that requires continuous monitoring [6]

Group 1 - Eli Lilly's GLP-1/GIP drug Tirzepatide (brand name: Mounjaro) has received approval from the National Medical Products Administration of China for use as a monotherapy in adults with type 2 diabetes, based on the SURPASS-CN-MONO study targeting early patients in China, which is expected to expand market potential in the country [1] - Eli Lilly's IL-23 monoclonal antibody, both intravenous and subcutaneous formulations, has been approved for the treatment of Crohn's disease and ulcerative colitis, enhancing its position in the immunology sector [1] Group 2 - In Q4 2025, Eli Lilly reported revenue of $19.29 billion, a 43% year-over-year increase, exceeding market expectations; adjusted earnings per share were $7.54, up 42% [2] - The Tirzepatide product line generated $36.5 billion in revenue for the year, making it the highest-selling drug globally; the company provided an optimistic revenue guidance for 2026, expecting a range of $80 billion to $83 billion, representing approximately a 25% year-over-year growth [2] Group 3 - Following the positive earnings report and product developments, Eli Lilly's stock experienced significant volatility, with a single-day increase of 10.33% on February 4, 2026, closing at $1,107.12; however, the stock closed at $1,015.21 on February 11, 2026, down 0.96%, with a total decline of 8.30% over the past five trading days, indicating a short-term market adjustment after the positive news [3] Group 4 - CICC released a report on February 10, 2026, noting that Tirzepatide has become the "king of drugs" in 2025, and Eli Lilly has a robust pipeline, with the oral GLP-1 drug Orforglipron expected to receive approval in Q2 2026, which could serve as a new growth driver; the report maintains a neutral rating with a target price of $1,107 [4] - Institutional data shows that 78% of market opinions are buy or hold, reflecting confidence in the long-term prospects of the GLP-1 sector [4]

Core Viewpoint - Novo Nordisk is advancing its weight loss pipeline with the addition of UBT251, a GLP-1/GIP/GCG tri-receptor agonist, which aims to enhance weight loss efficacy and metabolic improvements while addressing safety and tolerability concerns [6][8][11] Group 1: UBT251 Development - A global Phase II study for UBT251 has been registered, targeting 333 participants, with completion expected by January 2027 [6] - UBT251's long half-life of approximately 136 to 170 hours supports a once-weekly dosing regimen, showing superior weight loss compared to placebo in early trials [8] - The drug's tri-receptor approach aims to suppress appetite, improve glucose metabolism, and enhance energy expenditure for greater weight loss [6][8] Group 2: Competitive Landscape - The initiation of UBT251's Phase II trial coincides with heightened industry interest following Eli Lilly's Retatrutide Phase III results, which demonstrated significant weight loss and functional benefits [11] - Novo Nordisk's strategy includes leveraging its established GLP-1 system and commercial capabilities while responding to new competitive benchmarks set by emerging therapies [11] - The key focus for UBT251 in Phase II will be to achieve substantial weight loss while maintaining acceptable safety and tolerability profiles [11] Group 3: Financial and Strategic Considerations - In March 2025, Novo Nordisk entered a licensing agreement with a $200 million upfront payment and potential milestone payments up to $1.8 billion, reflecting a strategic investment in UBT251's potential [9] - This deal structure allows Novo Nordisk to manage initial cash outflows while betting on the drug's future clinical success to justify further investments [9]

Core Viewpoint - The article discusses Tencent's strategic investments in the GLP-1 weight loss drug sector, highlighting a comprehensive approach that integrates drug development with health management and data services, aiming for a long-term operational model in chronic disease management [5][10]. Investment Strategy - Tencent's investment strategy involves a phased approach, starting with near-commercial GLP-1 assets to secure stable cash flow from chronic disease management, particularly in diabetes and obesity, which have high repurchase rates and long management cycles [6][7]. - The second phase focuses on investing in next-generation technologies targeting multiple metabolic pathways, which could enhance weight loss effectiveness and improve long-term health outcomes [7][8]. - The third phase aims to diversify the technological pathways in weight loss solutions to mitigate risks associated with GLP-1 competition, ensuring a broader range of commercial opportunities [8][9]. Market Dynamics - The weight loss drug market presents significant opportunities due to its large and growing user base, which allows for long-term customer acquisition and service engagement across various health management aspects [9]. - There is a strong willingness to pay for weight loss solutions, transitioning from high-cost self-pay models to more diverse payment structures, including insurance and employer benefits, which enhances the market's accessibility [9]. - Weight management is interconnected with various chronic conditions, creating a comprehensive market for metabolic disease management, thus expanding the potential service offerings beyond just weight loss [9]. Infrastructure Development - Tencent's patent applications in health management and data processing indicate a focus on building a foundational infrastructure that connects drug efficacy with user engagement, enhancing long-term adherence and service delivery [10]. - The integration of detection, data, and service pathways is crucial for addressing the challenges of long-term adherence and monitoring in weight loss treatments, positioning Tencent to leverage its platform capabilities effectively [10]. Risk Preferences - Tencent's involvement with companies like Xianweida and Minwei Bio illustrates its risk appetite, balancing investments in more certain GLP-1 assets with those in innovative, multi-target approaches that offer greater potential for differentiation and market expansion [11][12]. - This dual strategy reflects a typical internet approach, combining stable assets with high-risk, high-reward opportunities while utilizing its technological and infrastructural advantages to enhance commercialization efficiency [12].

Group 1 - AbbVie submitted a new indication application for Upadacitinib to treat adult and adolescent non-segmental vitiligo to the FDA and EMA, potentially making it the first systemic drug for vitiligo globally [1] - AbbVie's total revenue for 2025 reached $61.16 billion, marking an 8.6% year-over-year increase, officially entering the $60 billion club [1] - Global sales of Upadacitinib amounted to $8.30 billion, reflecting a 39.1% year-over-year growth, while sales of Risankizumab reached $17.56 billion, up 49.9% [1] Group 2 - AbbVie's stock price fluctuated between $225.82 (highest on February 6) and $214.04 (lowest on February 5) during the week of February 5 to February 12, with a closing price of $223.19 on February 12, up 1.04% [2] - The pharmaceutical sector rose by 0.83% during the same period, while the Dow Jones index increased by 0.50% [2] Group 3 - AbbVie's immunology business generated $30.4 billion in revenue, a 14% year-over-year increase, becoming the core growth driver [3] - The neuroscience business has upgraded to a core pillar, with Vraylar generating $3.62 billion and Botox in the migraine field generating $3.77 billion [3] - The company acquired Capstan to gain access to the tLNP platform, positioning itself in the cutting-edge CAR-T therapy field [3] Group 4 - On February 5, multiple Wall Street firms updated their ratings, with TD Cowen maintaining a buy rating and a target price of $280, while Evercore lowered its target price to $228, and UBS maintained a hold rating with a target price of $230 [4] - Analysts are focusing on the company's pipeline progress and the potential for upward revisions in earnings guidance [4]

Core Insights - Pfizer's total revenue for 2025 was $62.6 billion, a 2% year-over-year decline, but core business revenue grew by 6% when excluding COVID-19 products, indicating robust growth in non-COVID segments [1] - Adjusted EPS for 2025 was $3.22, a 4% increase, driven by cost-cutting measures and improved operational efficiency [1] - The management reaffirmed its 2026 guidance, expecting revenue between $59.5 billion and $62.5 billion, with adjusted EPS projected at $2.80 to $3.00 [1] Financial Performance - In Q4 2025, Pfizer's revenue reached $17.6 billion, with a 9% year-over-year increase when excluding COVID-19 products, highlighting accelerated business transformation [1] - Non-COVID products like the anticoagulant Eliquis generated $8 billion in revenue (up 8%), and the pneumonia vaccine Prevnar contributed $6.5 billion, providing stable growth to offset declines in COVID-related sales [3] Market Analysis - According to a report by CMB International, Pfizer's Q4 performance exceeded expectations, with promising data from the weight-loss pipeline PF'3944 showing a 12.3% weight reduction in the mid-dose group, indicating competitive potential against Eli Lilly's tirzepatide [2] - Analyst ratings for Pfizer range from $26 to $30, with Scotiabank maintaining a "Buy" rating and a target price of $30, emphasizing improvements in cash flow and pipeline catalysts [2] Stock Performance - Over the past week (February 5 to 11, 2026), Pfizer's stock price fluctuated by 3.55%, with a range of $26.46 to $27.94, closing at $27.73 on February 11, reflecting a daily increase of 0.43% and a trading volume of $1.157 billion [4] - Year-to-date, Pfizer's stock has risen by 13.23%, outperforming the pharmaceutical sector, which saw a slight decline of 0.02% during the same period [4]